CCI Approves TPG Scion’s Acquisition of Schott Poonawalla Stake

06 Mar 2025 CW Team

TPG Scion SG Pte. Ltd. is a newly established special-purpose investment vehicle incorporated in Singapore on 11th October 2024, specifically for this transaction. Currently, it has no operational presence in India. It is affiliated with the TPG Group, a global, diversified investment firm founded in 1992. The TPG Group, which operates across multiple asset classes including private equity, real estate, and infrastructure, manages investments worldwide. The transaction is ultimately controlled by an entity advised by affiliates of TPG Inc., the ultimate holding company of the group.

Schott Poonawalla Private Limited (SPPL), the target company, is engaged in the development, manufacturing, and sale of pharmaceutical packaging solutions. Its product portfolio includes sterile and non-sterile glass containers such as ampoules, vials, cartridges, and prefilled syringes, which are critical components for the pharmaceutical and biotechnology industries. The company specialises in converting tubular glass into primary packaging solutions, ensuring high standards of safety and integrity for pharmaceutical formulations.

Strategic Importance of the Acquisition The acquisition aligns with TPG’s strategy of investing in high-growth sectors, particularly healthcare and life sciences. With India being a global leader in pharmaceutical manufacturing, the demand for high-quality primary packaging solutions has surged, driven by the rise in vaccine production, biologics, and injectable therapies.

The CCI’s approval paves the way for enhanced investments, technological advancements, and global expertise infusion in India's pharmaceutical packaging segment. The partnership between TPG and SPPL is expected to strengthen supply chain efficiencies, improve manufacturing capabilities, and support innovation in sterile and injectable packaging solutions.

Market and Industry Outlook India’s pharmaceutical packaging market is witnessing robust growth, propelled by increasing regulatory requirements, demand for biologics, and the rise of single-dose drug delivery systems. The expansion of vaccine production and the growth of biosimilars and novel therapies have amplified the need for advanced packaging solutions.

With global investors such as TPG entering the segment, the industry is poised for enhanced technological collaborations, automation in manufacturing, and sustainable packaging innovations. The acquisition of a stake in Schott Poonawalla Private Limited is expected to strengthen India’s position as a global hub for pharmaceutical packaging, ensuring compliance with stringent international standards while catering to the evolving needs of the pharmaceutical industry.

The Competition Commission of India (CCI) has approved the proposed acquisition of a stake in Schott Poonawalla Private Limited (SPPL) by TPG Scion SG Pte. Ltd., marking a significant development in the pharmaceutical packaging sector. The acquisition will be executed through a secondary share purchase from Serum Institute of India Private Limited. TPG Scion SG Pte. Ltd. is a newly established special-purpose investment vehicle incorporated in Singapore on 11th October 2024, specifically for this transaction. Currently, it has no operational presence in India. It is affiliated with the TPG Group, a global, diversified investment firm founded in 1992. The TPG Group, which operates across multiple asset classes including private equity, real estate, and infrastructure, manages investments worldwide. The transaction is ultimately controlled by an entity advised by affiliates of TPG Inc., the ultimate holding company of the group. Schott Poonawalla Private Limited (SPPL), the target company, is engaged in the development, manufacturing, and sale of pharmaceutical packaging solutions. Its product portfolio includes sterile and non-sterile glass containers such as ampoules, vials, cartridges, and prefilled syringes, which are critical components for the pharmaceutical and biotechnology industries. The company specialises in converting tubular glass into primary packaging solutions, ensuring high standards of safety and integrity for pharmaceutical formulations. Strategic Importance of the Acquisition The acquisition aligns with TPG’s strategy of investing in high-growth sectors, particularly healthcare and life sciences. With India being a global leader in pharmaceutical manufacturing, the demand for high-quality primary packaging solutions has surged, driven by the rise in vaccine production, biologics, and injectable therapies. The CCI’s approval paves the way for enhanced investments, technological advancements, and global expertise infusion in India's pharmaceutical packaging segment. The partnership between TPG and SPPL is expected to strengthen supply chain efficiencies, improve manufacturing capabilities, and support innovation in sterile and injectable packaging solutions. Market and Industry Outlook India’s pharmaceutical packaging market is witnessing robust growth, propelled by increasing regulatory requirements, demand for biologics, and the rise of single-dose drug delivery systems. The expansion of vaccine production and the growth of biosimilars and novel therapies have amplified the need for advanced packaging solutions. With global investors such as TPG entering the segment, the industry is poised for enhanced technological collaborations, automation in manufacturing, and sustainable packaging innovations. The acquisition of a stake in Schott Poonawalla Private Limited is expected to strengthen India’s position as a global hub for pharmaceutical packaging, ensuring compliance with stringent international standards while catering to the evolving needs of the pharmaceutical industry.

Infrastructure Transport

01 Jun 2026

MMRDA advances 250 m on Orange Gate–Marine Drive tunnel

The Mumbai Metropolitan Region Development Authority (MMRDA) has completed 250 m of underground tunnelling for the Orange Gate–Marine Drive Urban Road Tunnel using India’s largest slurry shield tunnel boring machine (TBM) deployed for an urban road project.The project involves twin tunnels extending over 7 km beneath critical transport corridors, including Central Railway, Western Railway and Metro Line 3. The work requires high-precision engineering to navigate densely developed urban infrastructure.Once completed, the tunnel is expected to reduce travel time between Orange Gate and Marin..

Infrastructure Urban

01 Jun 2026

Hindustan Zinc Pays Rs 188.46 Billion in FY26

Hindustan Zinc contributed Rs 188.46 billion to the public exchequer in FY 2025-26, according to its 9th Tax Transparency Report. The contribution, equivalent to 46 per cent of the company’s revenue, included direct and indirect taxes, government royalties, dividends to the Government of India, withholding taxes and other statutory levies.The company’s five-year cumulative contribution to the exchequer stood at Rs 915.72 billion. In FY26, Hindustan Zinc reported revenue of Rs 408.44 billion, EBITDA of Rs 221.62 billion and profit after tax of Rs 138.32 billion. It also achieved its highest..

Infrastructure Urban

01 Jun 2026

World of Concrete India 2026 Opens in Mumbai

Informa Markets in India will host the 12th edition of World of Concrete India 2026 from 3–5 June 2026 at the Bombay Exhibition Centre, Mumbai. The specialised B2B exhibition will bring together manufacturers, suppliers, contractors, developers, architects, consultants, infrastructure companies, project leaders and government stakeholders.The event is expected to feature over 350 brands and more than 18,000 trade professionals. It will cover concrete and cement, dry mortar, precast technologies, formwork, construction chemicals, industrial and commercial flooring, scaffolding, safety solutio..